ELI LILLY & Co is 481.0x more valuable than Day One Biopharmaceuticals, Inc. by market capitalization ($1.070 T vs $2.22 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | DAWN | LLY |
|---|---|---|
| Market cap | $2.22 B | $1.070 T |
| US-listed rank | #2029 | #10 |
| Revenue (latest FY) | $158.18M | $65.18B |
| Net income (latest FY) | -$107.32B | $20.64B |
| Net margin | -67847.2% | 31.7% |
| P/E (trailing FY) | - | 51.8 |
| SEC filings | 493 | 989 |
ELI LILLY & Co is 481.0x more valuable than Day One Biopharmaceuticals, Inc. by market capitalization ($1.070 T vs $2.22 B).
In their latest fiscal years, Day One Biopharmaceuticals, Inc. reported $158.18M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Day One Biopharmaceuticals, Inc. and ELI LILLY & Co, or browse the full rankings.